Bacillus subtilis 168 is the only bacterium-based host serving for the cloning of giant DNA above 1.000 kbp. As rapid verification of the genome structure is crucial during the cloning process, six of 18-base sequence recognized by endonuclease I-SceI were sequentially created in the B. subtilis 168 genome. The established method and materials should be of use for other B. subtilis derivatives.
serves as a common cloning locus for various guest genomes. 1, 2, 5, 7) In genome-order cloning study, it is crucial to confirm the genome structures not only of the guest but also the host. Presently available multiplex PCR and powerful sequencer analysis give information on the presence of identified DNA molecule, but the continuity as a single long DNA is hardly assured and therefore less is appropriate for inspection of local structural disorders possibly introduced during cloning. In contrast, digestion with certain endonucleases followed by pulsed-field gel electrophoresis (PFGE) offers rapid and convincing results. 1, 2) However, rare-cutting endonucleases such as NotI (5 0 -GCGGCC/GC-3 0 ), SfiI (5 0 -GGCCNNNN/ NGGCC-3 0 ), and Sse8387I (5 0 -CCTGCA/GG-3 0 ) are not appropriate for screening purposes, because there are too many fragments to be analyzed (Fig. 1) . Instead, two commercially available endonucleases, I-SceI (5 0 -TAG-GGATAA/CAGGGTAAT-3 0 ) and I-PpoI (5 0 -ATGAC-TCTCTTAA/GGTAGCCAAA-3 0 ) were chosen due to their absence in the host genome and most of the guest genomes, although I-PpoI has been utilized to verify guest genome structures in the BGM vectors, 1,2) I-SceI remains of limited use. 8, 9) Hence multiple I-SceI sites up to six were created in the host genome in this study. Six Sse8387I sites in the B. subtilis genome were selected ( Fig. 1 ) so as to produce I-SceI fragments well resolved by a single PFGE (Fig. 2) .
The I-SceI recognition sequence can be created easily by the insertion of an antibiotic resistance gene carrying the sequence. Two antibiotic resistance gene cassettes, neomycin (neo with I-SceI) and spectinomycin (spc with I-SceI), were constructed to create sequences at the two designed genome loci. 8, 9) But this method apparently required numbers of antibiotic resistance genes equal to those of the I-SceI site to be created. Seven other antibiotic resistance gene cassettes are currently available for B. subtilis selection: chloramphenicol (cat), tetracycline (tet), erythromycin (erm), blasticidin S (bsr), kanamycin (kam), phleomyicn (phl), and hygromycin (hyg). Since antibiotic resistance genes had to be saved for the guest genome cloning steps and the following manipulations, 1, 2) those allotted to the host genome had to be held to be a minimum. To this end, a gene-directed mutagenesis method (GDM) highly effective for B. subtilis 10) was applied. GDM was invented to introduce multiple mutations at various loci of the B. subtilis genome by the alternative use of limited numbers of antibiotic resistance cassettes. 10, 11) Two kinds of DNA fragment are needed to conduct sequential GDM for the Sse8387I!I-SceI conversion. One is a fragment possessing Sse8387I site called Sse8387I-linking clone. The other is a fragment carrying the leuB gene to conduct the auxotrophic marker change leu þ ,leuB::tet.
The six Sse8387I-linking clones, named pFAST, were isolated from a genomic EcoRI DNA library for B. subtilis strain BEST4087 11) created on the basis of a pBR322-based plasmid pBEST504. They were prepared by a method described previously.
11) The genomic locations of these six linking clones are shown in Fig. 1 . Two plasmids were constructed from each pFAST, one having a neomycin resistance gene (neo) inserted in the Sse8387I site and the other a synthetic I-SceI linker in the corresponding Sse8387I site. For the former, a neo gene cassette prepared by PstI digestion from pBEST512, 11) was ligated directly into the Sse8387I site 8) was inserted directly into the Sse8387I site of pFAST. An E. coli plasmid, RSF2124-leuB carrying the leuB gene from B. subtilis 168 (Fig. 1) , was used for the auxotrophic marker change. pBMAP105TT (leuB::tet) was derived from RSF2124-leuB by inserting a tetracycline resistance determinant gene (tet) in the BglII site of the leuB gene. 12) Transformation by pBMAP105TT produced a tetracycline-resistant B. subtiils transformant (leuB::tet), selected on an LB plate supplemented with tetracycline at 10 mg/mL. The leucin auxotrophic strain was converted to leu þ by the RSF2124-leuB plasmid at the next transformation. The leuB::tet!leu þ transformtans, selected on a Spizizen plate in the absence of leucin, were verified to be sensitive to tetracycline.
Positive selections in the conversion leu þ ,leu::tet can be repeated unlimited times. All the plasmids were prepared in E. coli grown in LB supplemented with ampicilin at 50 mg/mL. Endonucleases and T4 DNA ligase were purchased from Toyobo (Tokyo, Japan), except for Sse8387I, from Takara Shuzo (Kyoto, Japan), and I-SceI from Boehringer Mannheim (Indianapolis, USA).
The genomic Sse8387I site in the acoL gene of pFAST6 (Fig. 1) was marked with the neo gene. pFAST6A (acoL::neo) in transformation of B. subtilis strain CU741 11) yielded BEST3074 (acoL::neo), which was resistant to neomycin at 10 mg/mL. The protocols for the preparation and transformation of competent B. subtilis at 37 C are described previously. 11) In the transformation of BEST3074, two plasmids, pBMAP105TT (leuB::tet) and pFAST6S (acoL::I), were added simultaneously. The I-SceI linker insertion at the Sse8387I site of the gene acoL was designated acoL::I. Genotype description of the I-SceI linker insertion was similarly designated below. Due to a high frequency of simultaneous incorporation of the two fragments by B. subtilis competent cells, leuB::tet transformants selected by tetracycline were screened for sensitivity to neomycin caused by the acoL::neo!acoL::I conversion. BEST3075 (acoL::I, leuB::tet) was obtained at a frequency of 6% among the tetracycline-resistant colonies. Creation of the I-SceI in the acoL gene was completed.
The second I-SceI in the dctB carried by pFAST5 was done as: pFAST5A (dctB::neo) and RSF2124-leuB (leu þ ) were added to competent BEST3075. Colonies formed on Spizizen plate to select leuB::tet!leu þ were screened for ones resistant to neomycin. The neomycin resistant BEST3076 (dctB::neo, acoL::I, leu þ ) was obtained. The dctB::neo was converted to dctB::I by simultaneous use of two plasmids, pBMAP105TT (leuB::tet) and pFAST5S (dctB::I) in BEST3076 transformation. Colonies formed on tetracycline plate, leu þ !leuB::tet, were screened for ones sensitive to neomycin corresponding to dctB::neo!dctB::I. BEST3077 (dctB::I, acoL::I, leuB::tet) was isolated at a frequency of 8% of the tetracycline-resistant transformants.
Insertion of the 3 rd I-SceI site in the yvnB gene of pFAST7 was done similarly. Marking with neo by pFAST7A (yvnB::neo) and leuB::tet!leu þ by RSF2124-leuB (leu þ ) yielded BEST3084 (yvnB::neo, dctB::I, acoL::I, leu þ ). Simultaneous use of the pBMAP105TT (leuB::tet) and pFAST7S (yvnB::I) in BEST3084 transformation gave BEST3085 (yvnB::I, dctB::I, acoL::I, leuB::tet). The 4 th Sse8387I site in xkdE of the pFAST1 was similarly converted to I-SceI via xkdE::neo. Strain BEST3087 (xkdE::I, yvnB::I, dctB::I, acoL::I, leuB::tet) was found among 2% of the tetracycline-resistant transformants. The 5 th Sse8387I in the araM of pFAST2 was marked by neo in BEST3088 (araM::neo, xkdE::I, yvnB::I, dctB::I, acoL::I, leu þ ). Conversion of araM::neo to araM::I was carried out by pFAST2S (araM::I) and pFAST3B (yddT::bsr(I)). pFAST3B (yddT::bsr(I)) was used instead of pBMAP105TT (leuB::tet) to convert araM::neo! araM::I. pFAST3B was chosen to create the 6 th I-SceI site and to terminate GDM leaving leu þ . A blasticidin S-resistant gene (bsr(I)) carrying I-SceI, isolated from a pBEST402 derivative (unpublished plasmid) was in- 1N   15N   26N   8N   17N   25N   6N   33N   27N   12N   31N   2N   3N   30N 14N  9N  24N  22N   29N   18N   7N   19N   32N   13N   28N   23N   11N   21N   20N   4N   16N  5N  10N   2S   3S   4S   5S   6S   7S   8S   9S   10S  11S   12S   13S   14S   15S  16S   17S   18S   19S   20S   21S   22S   23S   24S   25S   26S   27S  28S   29S   30S   31S   32S   33S   34S   35S   36S  37S   38S   39S   40S  42S   45S   46S   47S   48S   50S   51S 1S serted in the Sse8387I site of the yddT of pFAST3, resulted in pFAST3B. Transformants selected by blasticidin S at 400 mg/mL acquired I-SceI in the yddT. Three percent of the blasticidin S-resistant colonies, yddI::bsr(I), exhibited sensitivity to neomycin equivalent to araM::neo!araM::I converted by pFAST2S (araM::I). Obtained was a representative strain BEST3091 (yddT::bsr(I), araM::I xkdE::I, yvnB::I, dctB::I, acoL::I, leu þ ) that possessed six I-SceI at the designated loci of the B. subtilis genome (Fig. 1). Step-by-step I-SceI acquisition was confirmed by the altered sizes and numbers of I-SceI fragments presented (Fig. 2) . Preparation of the genomes in agarose plug and enzyme digestion were done according to a protocol reported previously.
11)
The entire process for the six I-SceI insertions was simple and rapid and is readily applicable to B. subtilis 168 derivatives, for example restriction-modification deficient strain RM125. 13, 14) The present set of genes did not affect competence development and caused no deterioration in growth when inactivated by I-SceI linker insertion. B. subtilis strains with multiple I-SceI sites can be used as BGM vectors to meet demands in cloning and manipulation in various forms of guest genome cloning. The position of the I-SceI insertion can be redesigned in regions between genes, particularly when B. subtilis strains with reduced genomes are used as future BGM vectors. 15) 
